Brief: Medmix AG Targets 5% To 7% Growth In Revenue In 2023
Feb 22 (Reuters) - medmix AG MEDX.S :
* TARGETS 5% TO 7% GROWTH IN REVENUE IN 2023
* MEDMIX - DUE TO NEW PRODUCTION FACILITIES IN SPAIN AND US
AND
PLANNED INVESTMENTS IN RESEARCH AND DEVELOPMENT, MEDMIX
INDICATES AN ELEVATED CAPITAL EXPENDITURE LEVEL AT 14% OF
REVENUE IN 2023
* FOR FINANCIAL YEAR OF 2022, MEDMIX PROPOSES TO PAY A
DIVIDEND OF
CHF 0.50 PER SHARE
Further company coverage: MEDX.S
((Reuters.Briefs@thomsonreuters.com;))